Videos
Videos
Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention: The REDUCE-IT Trial – Q and A
Prof Bhatt answers questions received from the audience before and during the live webinar on Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention: The REDUCE-IT Trial.
For the best learning experience, we recommend watching the KOL masterclass on/demand video in addition to this video.
Infographics
Articles
Case Studies
Case Studies
Quiz of the month – February 2023
Take our patient case study quiz specially curated for you by our Faculty Member, Prof. Stephen Nicholls.
Case Study: A 58-year-old overweight man with a 10-year history of primary hypercholesterolemia presents for a checkup. At diagnosis of hypercholesterolemia, his LDL-C was 198 mg/dL; his clinician recommended diet and exercise interventions and started atorvastatin 10 mg qd. The patient follows a low saturated-fat diet and exercises daily. However, he could not tolerate higher doses of atorvastatin or rosuvastatin 5 mg or pravastatin 20 mg. Today, his LDL-C is 138 mg/dL, HDL-C 52 mg/dL, and triglycerides 78 mg/dL. He continues to take atorvastatin 10 mg qd.
You add ezetimibe, and follow-up bloods a month later show an LDL-C of 108 mg/dl. You are not sure if he has ASCVD, so review of prior imaging shows he had a CT scan a year ago to evaluate shortness of breath, and the report comments that he has “moderate coronary artery calcification”. You check and Lp(a) and it is elevated at 200 nmol/L (upper limit of normal is 75 nmol/L).
Case Studies
Quiz of the month – August 2022
Take our patient case study quiz specially curated for you by our Faculty Member, Prof. Stephen Nicholls.
Case Study: A 63 year old man presents for review after experiencing an inferior myocardial infarction 6 months previously with successful PCI and stenting to the right coronary artery. Angiography revealed minor coronary disease involving the left anterior descending and circumflex arteries. He has a background of hypertension and type 2 diabetes mellitus.
His current medications include aspirin 100 mg daily, ticagrelor 90 mg bd, atorvastatin 80 mg daily, metformin 1000 mg daily, empagliflozin 10 mg daily, perindopril 5 mg daily and metoprolol 25 mg bd.
His biochemistry revealed HbA1c 6.8%, LDL-C 70 mg/dL, HDL-C 37 mg/dL and triglycerides 225 mg/dL.
